GSK Snaps Up US Biotech Rapt Therapeutics for $2.2bn
GSK just made its first big move under new boss Luke Miels—and it’s a chunky one….
-
-
AstraZeneca Hits Pause on £200m Cambridge Expansion: What’s Really Going On?
When a pharmaceutical giant worth billions suddenly pumps the brakes on a £200 million investment, you…
